Abstract: A spoonable fermented cream cheese composition with high protein content, of the quark or skyr type, intended for persons requiring increased intakes of proteins, such as sportspersons and elderly persons. The composition comprises at least 8% by weight proteins, with respect to the total weight of the composition, the proteins consisting of a mixture of casein and milk serum proteins in a weight ratio between 50/50 and 75/25, the milk serum proteins comprising at least 20% denatured serum proteins in the form of microparticles, by weight with respect to the total weight of the serum proteins, and in that the pH is less than or equal to 4.6.

Abstract: Antibody specific for a 5-HTOL compound. A glucuronide with 5-hydroxytryptophol (5-HTOL) characterized in that it comprises the structure of the ?-glucuronide between the 5-hydroxy group of 5-HTOL and D-glucopyranosiduronic acid. An immunoassay and a diagnostic method utilizing the immunoassay wherein a 5-hydroxytryptophol (5-HTOL) compound is determined by the use of an antibody specific for a 5-HTOL compound is used.

Abstract: Antibody specific for a 5-HTOL compound. A glucuronide with 5-hydroxytryptophol (5-HTOL) characterized in that it comprises the structure of the ?-glucuronide between the 5-hydroxy group of 5-HTOL and D-glucopyranosiduronic acid. An immunoassay and a diagnostic method utilizing the immunoassay wherein a 5-hydroxytryptophol (5-HTOL) compound is determined by the use of an antibody specific for a 5-HTOL compound is used.

Abstract: Antibody specific for a 5-HTOL compound. A glucuronide with 5-hydroxytryptophol (5-HTOL) characterized in that it comprises the structure of the &bgr;-glucuronide between the 5-hydroxy group of 5-HTOL and D-glucopyranosiduronic acid. An immunoassay and a diagnostic method utilizing the ummunoassay wherein a 5-hydroxytryptophol (5-HTOL) compound is determined by the use of an antibody specific for a 5-HTOL compound is used.

Abstract: Methods and pharmaceutical compositions in unit dosage form for treating neurodegeneration in a human or non-human animal afflicted therewith wherein the active agent is a therapeutically effective amount of a polyamine having the formula: ##STR1## or a salt thereof with a pharmaceutically acceptable acid wherein: R.sub.1 and R.sub.6 may be the same or different and are hydrogen, alkyl, hydrocarbyl aryl, hydrocarbyl aryl alkyl, cycloalkyl, or any of the foregoing wherein the alkyl chain is interrupted by at least one etheric oxygen atom;N.sup.1, N.sup.2, N.sup.3 and N.sup.4 are nitrogen atoms capable of protonation at physiological pH's;a and b may be the same or different and are integers from 1 to 4;A, B and C may be the same or different and are bridging groups of variable length.